ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 288 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 0.47 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $17,948,748 | -7.2% | 503,330 | -33.9% | 0.05% | -21.0% |
| Q1 2023 | $19,333,134 | +73404.4% | 761,147 | +17.2% | 0.06% | -42.6% |
| Q4 2022 | $26,302 | -94.9% | 649,548 | +4031.7% | 0.11% | +5300.0% |
| Q3 2022 | $520,000 | -96.6% | 15,721 | -96.3% | 0.00% | -92.3% |
| Q2 2022 | $15,316,000 | +2103.7% | 425,842 | +2915.5% | 0.03% | +1200.0% |
| Q1 2022 | $695,000 | -93.2% | 14,122 | -90.8% | 0.00% | -92.3% |
| Q4 2021 | $10,244,000 | +17.3% | 154,298 | +10.5% | 0.03% | +18.2% |
| Q3 2021 | $8,730,000 | -40.3% | 139,628 | -20.7% | 0.02% | -40.5% |
| Q2 2021 | $14,611,000 | +326.5% | 176,050 | +241.3% | 0.04% | +362.5% |
| Q1 2021 | $3,426,000 | -82.0% | 51,588 | -79.3% | 0.01% | -75.0% |
| Q4 2020 | $19,075,000 | +4854.5% | 248,657 | +2678.3% | 0.03% | +3100.0% |
| Q3 2020 | $385,000 | -32.2% | 8,950 | -32.2% | 0.00% | -50.0% |
| Q2 2020 | $568,000 | -65.3% | 13,200 | -76.8% | 0.00% | -71.4% |
| Q1 2020 | $1,637,000 | – | 57,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |